PMVP · PMV Pharmaceuticals, Inc.

Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee.

Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.

Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2026.

Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.

Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.

Excludes 305,667 shares previously reported as held directly by the reporting person which were re-registered on August 13, 2025 and are now held of record by the Mack-Mulligan Revocable Trust (the "Revocable Trust").

The shares subject to the option are fully vested and immediately exercisable.

These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.

This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.

This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee.

Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.

Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2025.

Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2025.

Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2025.

The shares subject to the option are fully vested and immediately exercisable.

The shares subject to the option are fully vested and immediately exercisable.

The reported shares were sold to cover the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

These reported shares were sold to cover the reporting person's tax obligation in connection with the vesting of restricted stock units, or RSUs.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 22,674 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 22,674 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 125,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 125,000 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 27,200 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 27,200 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 249,600 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 249,600 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 75,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 75,000 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on June 12. 2023.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 330,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 330,000 shares, having an exercise price of $1.48 per share.

One-fourth of the shares subject to the option vest on August 13, 2025 and 1/48th vest monthly thereafter.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 125,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 125,000 shares, having an exercise price of $1.48 per share.

One-fourth of the shares subject to the option vest on August 13, 2025 and 1/48th vest monthly thereafter.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 13,605 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 13,605 shares, having an exercise price of $1.48 per share.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 27,200 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 27,200 shares, having an exercise price of $1.48 per share.

One-third of the shares subject to the option vest on August 13, 2025 and 1/36th vest monthly thereafter.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 134,584 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 134,584 shares, having an exercise price of $1.48 per share.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 249,600 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 249,600 shares, having an exercise price of $1.48 per share.

One-third of the shares subject to the option vest on August 13, 2025 and 1/36th vest monthly thereafter.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 75,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 75,000 shares, having an exercise price of $1.48 per share.

One-fourth of the shares subject to the option vest on August 13, 2025 and 1/48th vest monthly thereafter.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 13,605 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 13,605 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 330,000 shares of PMV common stock granted to the reporting person on May 12, 2023. In exchange, the reporting person received a replacement option, for 330,000 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2023.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 134,584 shares of PMV common stock granted to the reporting person on May 12, 2021. In exchange, the reporting person received a replacement option, for 134,584 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.

On August 13, 2024, the issuer cancelled, pursuant to the issuer's option exchange program, an option for 68,100 shares of PMV common stock granted to the reporting person on February 10, 2022. In exchange, the reporting person received a replacement option, for 68,100 shares, having an exercise price of $1.48 per share.

Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022.